Gene therapy company Genprex (NASDAQ: [[ticker:GNPX]]) has added two new executives to its management team: Catherine Vaczy as chief strategy officer and Michael Redman as chief operating officer. Both are executive vice presidents. Vaczy most recently provided strategic advisory services to early stage biotechnology companies. Previously she co-founded and served for a decade on the … Continue reading “Genprex Adds Chief Strategy Officer, Chief Operating Officer to C-Suite”
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer
Epizyme (NASDAQ: [[ticker:EPZM]]) has appointed Jeffery Kutok as its chief scientific officer to guide the Cambridge, MA-based company’s scientific strategy following the FDA’s approval earlier this year of its first drug as a treatment for epithelioid sarcoma. Kutok was most recently executive vice president and chief scientific officer at Infinity Pharmaceuticals (NASDAQ: [[ticker:INFI]]), which is also based in … Continue reading “Epizyme Names Infinity’s Jeffery Kutok as Chief Scientific Officer”
Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown
The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans. “I think that fear of losing out has pretty much gone out the window right now,” said Equillium (NASDAQ: [[ticker:EQ]]) CEO Bruce Steel in a phone interview with Xconomy, speaking generally of investor appetite. “I think … Continue reading “Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown”
Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic
Keros Therapeutics, a biotech which raised more than $50 million this month in venture capital, is now looking to tap the public markets for additional cash amid a time of historic tumult. The Lexington, MA-based company, is a clinical-stage biotech that aims to develop new treatments for patients with blood and musculoskeletal disorders by developing … Continue reading “Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic”
UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity
A group of scientists and physicians at UC San Diego Health and the UCSD School of Medicine has arranged a partnership with five diagnostics markers that it says will bring the health system’s capacity to test for coronavirus to as many as 1,500 tests daily sometime in early April. Amid a lack of available tests … Continue reading “UCSD, 5 Diagnostic Makers Partner to Ramp COVID-19 Testing Capacity”
Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More
The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play as communities around the world attempt to slow its spread. Xconomy, as always, is focused on the stories coming out of the life sciences community. … Continue reading “Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More”
Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies
Eureka Therapeutics, which has been developing methods to facilitate the development of cell therapies that can treat solid cancers, has raised $45 million to prove out its technologies in the clinic. To enhance its chances of success, the Emeryville, CA-based company has struck an agreement to work with Lyell Immunopharma, another San Francisco Bay Area … Continue reading “Eureka Partners With Lyell to Tackle Tricky Solid Tumor Cell Therapies”
How San Diego Biotech Leaders Are Adapting to Coronavirus Concerns
Three hundred Takeda employees from the Japanese pharma giant’s California research center have been working from home for 10 days straight. Neurocrine Biosciences, one of the few commercial-stage biotechs in town, is working to ensure the animals housed in its vivarium are appropriately minded. Ciara Kennedy, CEO of clinical-stage antifungal therapy developer Amplyx, is facing … Continue reading “How San Diego Biotech Leaders Are Adapting to Coronavirus Concerns”
Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer
Morphic Therapeutic (NASDAQ: [[ticker:MORF]]) on Tuesday named Peter Linde as its chief medical officer. Linde was most recently vice president of medical research at Acceleron Pharma (NASDAQ: [[ticker:XLRN]]), where he oversaw the design and execution of clinical trials including late-stage development work on luspatercept, a drug the FDA approved last year for patients with the … Continue reading “Morphic Appoints Acceleron’s Peter Linde as Its Chief Medical Officer”
AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening
Vancouver-based biotech AbCellera Biologics has identified more than 500 antibodies that could potentially be turned into medicines to treat the SARS-CoV-2 novel coronavirus. Now scientists at the National Institutes of Health (NIH), with which the company has been working to prepare medical countermeasures for pandemic outbreaks, are testing the candidates to determine which are most … Continue reading “AbCellera’s Coronavirus “Neutralizing” Antibody Leads Enter Screening”
Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs
Dutch molecular diagnostics company Qiagen said Tuesday it would “dramatically” ramp up production of the components needed for the RNA extraction kits used to detect the novel coronavirus in a patient sample. Isolating genetic material from a biological sample is a key step in the testing process, which has not been widespread in the US … Continue reading “Qiagen Juices RNA Extraction Kit Capacity to Feed Coronavirus Test Needs”
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
On Monday Danish company Novo Nordisk announced it would stop treating patients enrolled in clinical trials evaluating an investigational hemophilia drug it developed after three of those receiving the drug reported “thrombotic events.” Hemophilia, an inherited blood disorder, is characterized by low levels of proteins called clotting factors, which help patients’ blood to clot appropriately. … Continue reading “Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy”
UC San Diego Health Develops COVID-19 Test, Begins Testing Patients
The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the novel coronavirus in about eight hours. Developed under guidance that the FDA published roughly two weeks ago amid the severe shortage of tests for the viral illness, COVID-19, UCSD Health developed and validated an in-house … Continue reading “UC San Diego Health Develops COVID-19 Test, Begins Testing Patients”
Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO
Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque Therapeutics, named John Cox its CEO. Cox has been Torque’s chief executive since late 2019. Previously Cox was the CEO of Bioverativ (NASDAQ: [[ticker:BIIV]]), which he spun out from Biogen (NASDAQ: [[ticker:BIIB]]) in 2016 and oversaw … Continue reading “Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO”
CureVac Founder Ingmar Hoerr to Replace CEO Dan Menichella
German biotech CureVac, a developer of messenger RNA-based drugs, said company founder Ingmar Hoerr would take over for CEO Dan Menichella. Menichella joined the company in 2017 to run its US operations, which are in Boston. He took over the CEO role from Hoerr in 2018. In its statement announcing the transition, CureVac credited Menichella … Continue reading “CureVac Founder Ingmar Hoerr to Replace CEO Dan Menichella”
Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders
Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it has been developing for oncology and autoimmune disorders. The Cambridge, MA-based company disclosed the strategy shift Thursday in its report of fourth quarter and full year 2019 financial results. After the announcement, shares of Rubius … Continue reading “Rubius Drops Rare Diseases, Turns to Cancer and Autoimmune Disorders”
Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline
A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its clinical-stage compounds and continue to build its portfolio of earlier-stage therapeutics. Shanghai-based Harbour BioMed emerged in 2016 after acquiring technology developed by Harbour Antibodies, a Dutch company that … Continue reading “Harbour BioMed Tacks on $75M to Advance Broad Biologics Pipeline”
Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug
In the four years that Silverback Therapeutics has been developing cancer immunotherapies that avoid dangerous side effects, the biotech has mostly kept a low profile. Now the company has $78.5 million in cash to advance that research, and it’s starting to open up about its work. The Series B round of funding brings the Seattle-based … Continue reading “Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug”
Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data
A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last August the FDA rejected a Kala (NASDAQ: [[ticker:KALA]]) product meant to temporarily relieve signs and symptoms of dry eye disease. On Monday the Watertown, MA-based biopharma announced preliminary results … Continue reading “Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data”
Senti Biosciences Appoints Jose Iglesias as Its Chief Medical Officer
Senti Biosciences named Jose Iglesias as its chief medical officer, tasked with overseeing the development of its cell and gene therapy product candidates for the treatment of solid and liquid tumors. Iglesias’s previous experience includes CMO and clinical development leadership roles at companies including Boston Biomedical, Apobiologix, Biothera Pharmaceuticals, Bionomics, Celgene, Abraxis BioScience, and Eli … Continue reading “Senti Biosciences Appoints Jose Iglesias as Its Chief Medical Officer”
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help meet that ambitious goal, and this week Gilead announced one of them: a nearly $5 billion deal for cancer immunotherapy developer Forty Seven. Forty Seven’s lead CD47-blocking drug—the company is named after the … Continue reading “Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More”
Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects
A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of infections related to a device used to take samples of cerebral spinal fluid during the trial. The suspension doesn’t appear to be related to … Continue reading “Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects”
MacroGenics Chief Medical Officer Jon Wigginton Announces Resignation
MacroGenics (NASDAQ: [[ticker:MGNX]]) says its chief medical officer, Jon Wigginton, will leave the Rockville, MD-based company as of March 27. The company said Wigginton, who joined MacroGenics in 2003, plans to resign “to pursue a new opportunity.” As MacroGenics, which is development antibody drugs for cancer, searches for a new CMO, its senior vice president … Continue reading “MacroGenics Chief Medical Officer Jon Wigginton Announces Resignation”
PsiOxus Therapeutics Appoints Tom Lillie as Chief Medical Officer
Gene therapy developer PsiOxus Therapeutics on Thursday announced it has appointed Tom Lillie as its chief medical officer. Lillie previously held senior oncology roles at Amgen (NASDAQ: [[ticker:AMGN]]) and MSD (NYSE: [[ticker:MRK]]) (as Merck is known outside of the US and Canada). The Oxford, England-based company also said it moved its third gene therapy for … Continue reading “PsiOxus Therapeutics Appoints Tom Lillie as Chief Medical Officer”
Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors
Cell therapies have helped treat some blood cancers, but toxic side effects are one limitation preventing their use in solid tumors. Amunix has, since its 2006 launch, licensed to biopharmas technology developed by company co-founder Volker Schellenberger to extend the half-life of some drugs while avoiding triggering an unwanted immune response. Now that technology has … Continue reading “Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors”
Sanofi Wins FDA Nod for Combo Therapy in Multiple Myeloma
The FDA on Monday approved a Sanofi antibody drug for adults with multiple myeloma whose disease hasn’t responded to at least two prior therapies, including the chemotherapy lenalidomide and a proteasome inhibitor. The drug, isatuximab-irfc (Sarclisa), was OK’d for patients in combination with pomalidomide, a chemotherapy, and dexamethasone, a corticosteroid (pom-dex). The Sanofi (NYSE: [[ticker:SNY]]) … Continue reading “Sanofi Wins FDA Nod for Combo Therapy in Multiple Myeloma”
ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers
With one investigational cancer drug in Phase 1 testing and a second one approaching the clinic, ORIC Pharmaceuticals is looking to tap the public markets for funds to finance that research. The company, which has set a preliminary target of about $86 million for its initial public offering, is looking to list on the Nasdaq … Continue reading “ORIC Pharma Plans IPO to Test Therapies for Drug-Resistant Cancers”
Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies
Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment. The Cambridge, MA-based neuroscience drug developer is paying gene editing company Sangamo Therapeutics (NASDAQ: [[ticker:SGMO]]) $350 million up front in a collaboration on potential one-time treatments for … Continue reading “Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies”
Passage Bio’s IPO Raises $216M to Fund Gene Therapy Studies
Gene therapy developer Passage Bio priced its initial public offering at $18 per share, raising $216 million—72 percent more than it originally planned to raise. Earlier this month Passage filed to offer 7.4 million shares, but later increased that to 10 million, then 12 million, shares that sold at the high end of its $16 … Continue reading “Passage Bio’s IPO Raises $216M to Fund Gene Therapy Studies”
XenoTherapeutics Names Michael Yaremchuk as Its Chief Medical Officer
XenoTherapeutics on Wednesday named its first chief medical officer, Michael Yaremchuk. Boston-based XenoTherapeutics is working to advance what’s known as xenotransplantation, or the process of grafting or transplanting organs or tissues between members of different species. Its first product to enter the clinic, Xeno-Skin, is genetically engineered pig skin intended to temporarily close human burn … Continue reading “XenoTherapeutics Names Michael Yaremchuk as Its Chief Medical Officer”
Halozyme Therapeutics Appoints SutroVax’s Elaine Sun as New CFO
Halozyme Therapeutics (NASDAQ: [[ticker:HALO]]) this week appointed Elaine Sun as its senior vice president and chief financial officer. Sun, who starts March 2, succeeds Laurie Stelzer, who joined Halozyme as CFO in 2015. Stelzer recently resigned to pursue another employment opportunity, according to Halozyme. Sun was most recently as chief financial officer and chief strategy … Continue reading “Halozyme Therapeutics Appoints SutroVax’s Elaine Sun as New CFO”
Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing
An investigational antiviral drug Gilead Sciences has been developing to treat infections caused by the Ebola virus will be tested in about 1,000 adults diagnosed with COVID-19, the novel coronavirus that has infected tens of thousands of people and killed more than 2,500. On Wednesday, Foster City, CA-based Gilead (NASDAQ: [[ticker:GILD]]) announced the start of … Continue reading “Gilead, Moderna Candidates Ramp Up Coronavirus Drug, Vaccine Testing”
Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data
About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. That day is here. Takeda (NYSE: [[ticker:TAK]]) acquired the company for an undisclosed amount up front, plus up to $330 million in payments … Continue reading “Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data”
NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data
In what looks to be a transformative year for potential treatments of nonalcoholic steatohepatitis, the liver disease better known as NASH, another biotech has revealed that its experimental drug appears to improve the condition compared to a placebo. NGM Biopharmaceuticals (NASDAQ: [[ticker:NGM]]) revealed preliminary data on Monday showing that 22 percent of patients who received … Continue reading “NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data”
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More
The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug. But insulin isn’t a chemical drug, it’s made from biological material. Under … Continue reading “Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More”
SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal
Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to add to its partnerships portfolio. On Wednesday, South San Francisco-based Five Prime (NASDAQ: [[ticker:FPRX]]) said it inked one such new deal. The agreement, a license deal … Continue reading “SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal”
Turning Point Taps eFFECTOR’s Reich as Its Chief Scientific Officer
Precision oncology company Turning Point Therapeutics (NASDAQ: [[ticker:TPTX]]) on Thursday said it has appointed Siegfried Reich as executive vice president and chief scientific officer. Reich, whose new role starts March 2, was most recently senior vice president of research at another San Diego-based cancer drug developer, eFFECTOR Therapeutics, which he co-founded. Reich’s experience includes time … Continue reading “Turning Point Taps eFFECTOR’s Reich as Its Chief Scientific Officer”
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases. EnClear Therapies has raised a $10 million Series A round of financing from a syndicate of investors to advance a device that it says could help treat neurodegenerative diseases by filtering out such proteins from cerebral spinal fluid (CSF), … Continue reading “EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device”
Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials
A Teva Pharmaceutical drug in testing as a treatment for tics in pediatric patients with moderate-to-severe Tourette syndrome has failed two late-stage trials. Israel-based Teva (NYSE: [[ticker:TEVA]]) said Wednesday that the drug, deutetrabenazine, didn’t beat a placebo in reducing motor and phonic tics—the main goals of the Phase 2/3 and Phase 3 trials. Those signs … Continue reading “Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials”
Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test
A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers. On Tuesday the company (NASDAQ: [[ticker:FPRX]]) said one of those drugs, cabiralizumab, a Five Prime antibody that Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) was testing in combination with its cancer immunotherapy … Continue reading “Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test”
Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics: price transparency and drug pricing reform. President Trump asserted that an executive order he signed last year directing various federal agencies to come up with new rules requiring … Continue reading “Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More”
Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO
Longtime Myriad Genetics (NASDAQ: [[ticker:MYGN]]) president and CEO Mark Capone has resigned. The Salt Lake City-based molecular diagnostic company said Myriad and Capone—who has been with the company for 17 years—mutually agreed it was the right time for a leadership transition. Bryan Riggsbee, Myriad’s chief financial officer, was appointed interim president and CEO. He will … Continue reading “Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO”
Ichnos Sciences Appoints Gabriela Gruia as Chief Development Officer
Ichnos Sciences named Gabriela Gruia as its chief development officer. Gruia was most recently senior vice president and head of regulatory affairs for the Novartis (NYSE: [[ticker:NVS]]) oncology business. Her experience includes previous roles at Pharmacia and Pfizer (NYSE: [[ticker:PFE]]). The Paramus, NJ, company is a spinout of Indian company Glenmark Pharmaceuticals that debuted in … Continue reading “Ichnos Sciences Appoints Gabriela Gruia as Chief Development Officer”
Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial
Scripps Research is charting new territory with its Calibr division, a drug discovery and drug development group within the research institute that is advancing its own experimental treatments. This week Calibr announced it had received the agency’s go-ahead to move a CAR-T cell therapy it has been evaluating for the treatment of certain blood cancers, … Continue reading “Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial”
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated. Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,” sold 9.25 million shares, up from the 6.25 million it said it planned to … Continue reading “Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered”
Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors
To have a therapeutic effect, drugs need to bind to proteins. But since it isn’t always possible to find an appropriate receptor, Coda Biotherapeutics is designing receptors, which it plans to deliver via engineered viruses, that respond only to a specific drug. On Wednesday the South San Francisco-based biotech announced it acquired a company called … Continue reading “Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors”
Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate
Last week the FDA approved an Aimmune Therapeutics drug for children with peanut allergies, the first oral immunotherapy for a food allergy to get the agency’s nod. On Wednesday the Brisbane, CA-based biotech announced that one of its backers, Nestlé Health Science, had made a new $200 million equity investment that it will use to … Continue reading “Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate”
Verily, Santen See Ophthalmology Opportunity Via New Joint Venture
Verily, the life sciences spinout of Google parent Alphabet, has inked a deal with a Japanese ophthalmology company to develop digital tools and technologies to improve eye health. Santen Pharmaceutical, which is based in Osaka, has a global industrial and commercial ophthalmology business. Teaming up with Verily will enable it to apply the South San … Continue reading “Verily, Santen See Ophthalmology Opportunity Via New Joint Venture”
Amylyx Pharmaceuticals Names Jeffrey Trigilio Chief Financial Officer
Amylyx Pharmaceuticals has appointed Jeffrey Trigilio to serve as its first chief financial officer. Trigilio was most recently vice president of finance at cell therapy company BlueRock Therapeutics. His previous experience includes time at Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]). Amylyx, which is based in Cambridge, MA, is developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s … Continue reading “Amylyx Pharmaceuticals Names Jeffrey Trigilio Chief Financial Officer”
Epirium Bio Names BioMarin’s Somaratne Its Chief Medical Officer
Epirium Bio, which recently raised $85 million to develop new drugs for disorders associated with mitochondrial depletion, appointed Ransi Somaratne as its chief medical officer. Somaratne was most recently core team leader for the BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) hemophilia A gene therapy program, where he led the group that has asked the FDA to review … Continue reading “Epirium Bio Names BioMarin’s Somaratne Its Chief Medical Officer”